PSYBF (PsyBio PNK) -99.98% to $0.000001 on 25 Feb 2026: next steps
PSYBF stock plunged -99.98% to $0.000001 on 25 Feb 2026 during U.S. market hours, marking one of the largest one-day declines among small-cap biotech names. Volume reached 8,000 shares versus an average of 16,227, while market cap stood at roughly $1,275.00 (USD) on the PNK exchange. The move pushed PsyBio Therapeutics Corp. (PSYBF) — a Healthcare/Biotechnology issuer — to the top losers list and tightened liquidity for traders and holders. We use Meyka AI-powered market analysis to connect key ratios, trading signals and price forecasts to today’s drop.
PSYBF stock: why the price collapsed today
The immediate fact: PSYBF fell from a previous close of $0.00500 to $0.000001 today, a -99.98% intraday change. That drop erased most market value and left the share count of 127,499,999 outstanding with a market cap near $1,275.00.
No scheduled earnings announcement is listed and EPS is -0.02, so the decline appears driven by extreme illiquidity and order imbalances rather than fresh public financial results. The daily low and high both registered at $0.000001, indicating sparse trading and potential price-feed volatility.
Key metrics and valuation for PSYBF stock
PsyBio’s trailing metrics show fragile fundamentals: EPS -0.02, price averages 50-day $0.00001 and 200-day $0.000069, and enterprise value is listed at $135,914.00. Current ratios and cash per share are extremely low; cash per share is about $0.000008, and book value per share is -0.01423.
Valuation multiples are not meaningful given the sub-penny price. Price-to-book, P/E and price-to-sales ratios are effectively zero or negative, which signals that standard valuation work has limited use until liquidity or operating results change materially.
Technicals and trading picture for PSYBF stock
Technical indicators show a flat or no-trend environment: RSI 51.85, ADX 4.83 (no trend), and on‑balance volume negative. Average volume was 16,227 but today’s volume was 8,000, reflecting half the usual flow and increased volatility risk.
With the stock trading at $0.000001, standard moving averages and oscillators lose practical meaning. Traders should treat price data as prone to quote anomalies, and watch for any change in quoted spreads or a resumption of normal volume before acting.
Meyka AI rates PSYBF with a score out of 100 and analyst view
Meyka AI rates PSYBF with a score of 62.58 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry comparisons, financial growth, key metrics, forecasts, analyst consensus and fundamental growth.
This internal grade reflects mixed signals: weak liquidity and negative EPS offset by a small enterprise value and potential sector interest in psychedelic-inspired therapeutics. These grades are informational and not financial advice.
Risks, catalysts and sector context for PSYBF stock
Primary risks are liquidity, quoted-price reliability and continued cash burn; the current ratio is 0.13 and interest coverage is deeply negative. Regulatory or trial updates in the psychedelic therapy sector could be catalysts, but none are scheduled in public filings today.
Sector performance in Healthcare/Biotechnology has shown selective strength, yet micro-cap names like PsyBio are vulnerable to rapid declines. Monitor company communications and exchange notices closely for delisting or corporate actions.
Trading implications and practical price targets for PSYBF stock
For active traders, manage size tightly and expect large bid-ask spreads. Short-term price targets should be framed as scenario ranges: a bear scenario near $0.000001, a base recovery target around $0.000010, and a stretch target near the year high $0.00500 if liquidity normalizes.
Use stop limits, limit orders and verify quotes before trade entry. For investors, any position sizing should assume potential total loss given the stock’s tiny market cap and fragile metrics.
Final Thoughts
Today’s collapse made PSYBF stock one of the top losers on 25 Feb 2026, with a one-day fall of -99.98% to $0.000001 (PNK, United States). Meyka AI’s forecast model projects $0.00 as the near-term system output, which compared with the current price of $0.000001 implies an effective downside to zero of -100.00%. That projection reflects our model’s zeroed monthly and yearly forecasts and the extremely thin liquidity profile. Practical outlook: short‑term traders should avoid aggressive sizing and wait for confirmed volume recovery and clearer exchange quotes. Long-term investors must see a sustainable cash or trial catalyst before reconsidering exposure. Forecasts are model-based projections and not guarantees. For company details visit the PsyBio website and additional company data sources such as FinancialModelingPrep. Meyka AI provides this analysis using real-time indicators and proprietary grading — use it as one input among many.
FAQs
Why did PSYBF stock fall so sharply today?
PSYBF stock dropped -99.98% to $0.000001 mainly due to extreme illiquidity and large order imbalances. No new public earnings or scheduled announcements explain the move; thin volume (8,000 shares) amplified price swings.
What is Meyka AI’s view of PSYBF stock?
Meyka AI rates PSYBF 62.58/100 (Grade B, HOLD). The score weighs benchmark and sector comparisons, financial growth, key metrics and forecasts. This is informational and not investment advice.
Are there realistic price targets for PSYBF stock?
Scenario targets: bear $0.000001, base $0.000010, stretch $0.00500 (year high). Targets assume restored liquidity and positive company catalysts; treat them as high-risk scenarios.
What should traders watch next for PSYBF stock?
Watch confirmed volume pickup, exchange notices, SEC filings and company announcements. Verify live quotes before trading and use limit orders because spreads and quote reliability are poor.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.